Add Presentation to Slide Tray Presentation:
Drug Therapy for Rheumatoid Arthritis in Adults
Authors: John I. Gomez, MD
Clinical Questions Addressed by the Comparative Effectiveness Review
The comparative effectiveness review addressed several key clinical questions, including:
- Do drug therapies for rheumatoid arthritis (RA) differ in their ability to reduce disease activity, to slow or limit the progression of joint damage, or to maintain remission?
- Do drug therapies for RA differ in their ability to improve patient-reported symptoms, functional capacity, or quality of life?
- Do drug therapies for RA differ in harms, tolerability, patient adherence, or adverse effects?
- What are the comparative benefits and harms of drug therapies for RA in subgroups of patients based on stage of disease, prior therapy, demographics, concomitant therapies, or comorbidities?
Keywords: rheumatoid arthritis | RA | DMARDs | disease-modifying | antirheumatic | anti-rheumatic | rheumatic | biologic | oral | demographics | comorbidities
- Donahue KE, Jonas D, Hansen RA, et al. Drug Therapy for Rheumatoid Arthritis in Adults: An Update. Comparative Effectiveness Review No. 55 (Prepared by the RTI International–University of North Carolina Evidence-based Practice Center under Contract No. 290-2007-10056-I). Rockville, MD: Agency for Healthcare Research and Quality; April 2012. AHRQ Publication No. 12-EHC025-EF. Available at www.effectivehealthcare.ahrq.gov/dmardsra.cfm.
Your slide tray is being processed.